Characteristics of included studies
| Study | Year of first publication | Participants | Treatments | Outcomes* | Notes |
|---|---|---|---|---|---|
| RITA-I | 1993 | Coronary artery disease Eligible for either treatment No previous revascularisation | Balloon angioplasty (510, 29 with diabetes) CABG (501, 33 with diabetes) | Primary: Composite† Secondary: all cause death 1, 5 years | Only 55% had multivessel disease Composite outcome did not include stroke Multicentre |
| EAST | 1994 | Multi-vessel disease No left main disease Eligible for either treatment | Balloon angioplasty (198, 49 with diabetes) CABG (194, 41 with diabetes) | Primary: all cause death 3, 8 years | Single centre |
| CABRI | 1995 | Multivessel disease No left main disease Eligible for either treatment No previous revascularisation | Balloon angioplasty plus BMS (541, 64 with diabetes) CABG (513, 60 with diabetes) | Primary: all cause death 4 years | Multicentre |
| BARI | 1996 | Multivessel disease Eligible for either treatment | Balloon angioplasty (915, 174 with diabetes, 76 on insulin) CABG (914, 183 with diabetes, 82 on insulin) | Primary: all cause death Secondary: composite, cardiovascular death 1, 3, 5, 10 years | Multicentre |
| AWESOME | 2001 | Multivessel disease Eligible for either treatment High-risk patients | Balloon angioplasty/BMS (222, 65 with diabetes) CABG (232, 79 with diabetes) | Primary: all cause death 1, 3 years | Use of stents changed from 26% to 88% during the 5 years of recruitment Multicentre |
| ERACI-II | 2001 | Multivessel disease Eligible for either treatment High risk patients | BMS (225, 39 with diabetes) CABG (225, 39 with diabetes) | Primary: MACCE Secondary: all cause death 1, 5 years | Only reported mortality for people with diabetes Multicentre |
| ARTS-I | 2001 | Multivessel disease Eligible for either treatment No previous revascularisation | BMS (601, 112 with diabetes, 23 on insulin) CABG (604, 96 with diabetes, 16 on insulin) | Primary: MACCE Secondary: all cause death, composite 1, 3, 5 years | Multicentre |
| SOS | 2002 | Multivessel disease Eligible for either treatment No previous revascularisation | BMS (488, 68 with diabetes) CABG (500, 74 with diabetes) | Primary: Revascularisation Secondary: all cause death, composite 1, 6 years | Multicentre |
| MASS-II | 2004 | Stable multivessel disease Eligible for either treatment | BMS (205, 56 with diabetes) CABG (203, 59 with diabetes) | Primary: MACCE Secondary: all cause death, cardiovascular death 1, 5 years | Diabetes either treated or high blood glucose on 2 occasions Single centre. |
| CARDia | 2010 | Multivessel disease or complex single vessel disease Eligible for either treatment Treated diabetes | PCI (256, all with diabetes, 92 on insulin) CABG (254, all with diabetes, 97 on insulin) | Primary: composite Secondary: all cause death, MACCE 1, 5 years | Started with BMS but DES used when they became available Multicentre |
| SYNTAX | 2010 | Multivessel disease or left main artery disease Eligible for either treatment | DES (903, 231 with diabetes, 88 on insulin) CABG (897, 221 with diabetes, 87 on insulin) | Primary: MACCE Secondary: All cause death, cardiovascular death, composite 3, 5 years | Randomisation stratified by diabetes status Multicentre |
| PRECOMBAT | 2011 | Left main artery disease | DES (300, 102 with diabetes, 10 on insulin) CABG (300, 90 with diabetes, 9 on insulin) | Primary: MACCE 2, 5 years | Individual components of MACCE not reported for the subgroup with diabetes Multicentre |
| FREEDOM | 2012 | Multivessel disease Eligible for either treatment Treated diabetes | DES (953, all with diabetes, 325 on insulin) CABG (947, all with diabetes, 277 on insulin) | Primary: composite Secondary: all cause death, cardiovascular death, MACCE. 1, 2, 3, 5 years | Multicentre |
| VA-CARDS | 2013 | Multi-vessel disease or left main artery disease Eligible for either treatment Treated diabetes | DES (104, all with diabetes) CABG (103, all with diabetes. | Primary: composite Secondary: all cause death, cardiovascular death 1, 2 years | Composite outcome did not include stroke Multicentre |
| BEST | 2015 | Multi-vessel disease No left main disease Eligible for either treatment | DES (438, 177 with diabetes) CABG (447, 186 with diabetes) | Primary: composite Secondary: all cause death | Used second generation (everolimus-eluting) stents |
*Many secondary outcomes are not listed.
†Composite of death, stroke or myocardial infarction unless otherwise specified.
BMS, bare metal stent; CABG, coronary artery bypass graft; DES, drug eluting stent; MACCE, Major Adverse Cardiac or Cerebrovascular Event.